ProTcell™ Platform

Smart Immune has developed T-cell progenitor-based cell and gene therapies to rapidly and fully reset patients’ immune systems to fight cancers and infections in the long run.


Smart Immune has replicated a Human lymphoid niche ex vivo using its knowledge of CD34+ T cell differentiation

A thymus-homing capability of unique T-cell progenitors so called ProTcell™ at the earliest point of lineage commitment.
A great capability of ProTcell to differentiate ex vivo in NK cells

The ability to culture and expand such  short-lived, fragile, unique T-cells populations in GMP conditions, using  proprietary Notch ligand SIFP3

Biomimicking first HSCs differentiation steps in 7 days ex vivo vs. in 12 months in human physiology

Enabling improved & Long-Lasting Cellular Immunotherapies

The ProTcell™ can be used with or without CAR/TCR transduction giving rise, when infused to patients, to the first long lasting cell therapy drug product, improving significantly the clinical outcome for the patients.

Key scientific publications

Non-clinical publications

A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors.
Moirangthem RD, Ma K, Lizot S, Cordesse A, Olivré J, de Chappedelaine C, Joshi A, Cieslak A, Tchen J, Cagnard N, Asnafi V, Rausell A, Simons L, Zuber J,Taghon T, Staal F, Pflumio F, Six E, Cavazzana M, Lagresle-Peyrou L, Soheili T and André I.
Cell Mol Immunol (2021)18:1662–1676. doi: 10.1038/s41423-021-00706-8.

A human postnatal lymphoid progenitor capable of circulating and seeding the thymus.
Six EM, Bonhomme D, Monteiro M, Beldjord K, Jurkowska M, Cordier-Garcia C, Garrigue A, Dal Cortivo L, Rocha B, Fischer A, Cavazzana-Calvo M, André-Schmutz I.
J Exp Med. 2007 Dec 24;204(13):3085-93. Epub 2007 Dec 10.

Notch ligands Delta and lymphoid development niches.
Six E, André Schmutz I, Cavazzana-Calvo M.
Med Sci (Paris). 2007 Jan;23(1):21-4. French. No abstract available.

Human T-lymphoid progenitors generated in a feeder-cell-free Delta-like-4 culture system promote T-cell reconstitution in NOD/SCID/γc(-/-) mice.
Reimann C, Six E, Dal-Cortivo L, Schiavo A, Appourchaux K, Lagresle-Peyrou C, de Chappedelaine C, Ternaux B, Coulombel L, Beldjord K, Cavazzana-Calvo M, Andre-Schmutz I.
Stem Cells. 2012 Aug;30(8):1771-80. doi: 10.1002/stem.1145.

Generation of adult human T-cell progenitors for immunotherapeutic applications.
Simons L, Ma K, de Chappedelaine C, Moiranghtem RD, Elkaim E, Olivré J, Susini S, Appourchaux K, Reimann C, Sadek H, Pellé O, Cagnard N, Magrin E, Lagresle-Peyrou C, Taghon T, Rausell A, Cavazzana M, André-Schmutz I.
J Allergy Clin Immunol. 2018 Apr;141(4):1491-1494.e4. doi: 10.1016/j.jaci.2017.10.034. Epub 2017 Dec 5. No abstract available.

Clinical publications

Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy.
André I, Simons L, Ma K, Moirangthem RD, Diana JS, Magrin E, Couzin C, Magnani A, Cavazzana M.
Bone Marrow Transplant. 2019 Aug;54(Suppl 2):749-755. doi: 10.1038/s41409-019-0599-9. Review.

Concise Review: Boosting T-Cell Reconstitution Following Allogeneic Transplantation-Current Concepts and Future Perspectives.
Simons L, Cavazzana M, André I.
Stem Cells Transl Med. 2019 Jul;8(7):650-657. doi: 10.1002/sctm.18-0248. Epub 2019 Mar 18. Review.

Advances in adoptive immunotherapy to accelerate T-cellular immune reconstitution after HLA-incompatible hematopoietic stem cell transplantation.
Reimann C, Dal Cortivo L, Hacein-Bey-Abina S, Fischer A, André-Schmutz I, Cavazzana-Calvo M.
Immunotherapy. 2010 Jul;2(4):481-96. doi: 10.2217/imt.10.36. Review.